Seaport Therapeutics, Inc. (SPTX) is a pioneering biopharmaceutical firm dedicated to addressing significant unmet medical needs through the development of innovative immune-oncology therapies. Utilizing advanced technologies and a comprehensive research pipeline, the company focuses on creating targeted treatment options for complex diseases, especially cancer. Seaport's strategic collaborations and partnerships enhance its capabilities within the dynamic therapeutics sector, while its experienced management team drives its mission to improve patient outcomes and transform the landscape of cancer treatment. With a clear commitment to scientific advancement, Seaport Therapeutics is poised to play a vital role in the future of immunotherapy.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-96.02M |
| Operating Margin | 0.00% |
| Return on Equity | -28.10% |
| Return on Assets | -18.90% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-44.55 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $53.53M |
| Float | $28.33M |
| % Insiders | 35.06% |
| % Institutions | 31.86% |
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™.
BOSTON--(BUSINESS WIRE)--Seaport Therapeutics to participate in two upcoming investor conferences.
PureTech Health (LSE:PRTC, NASDAQ:PRTC, OTC:PTCHF, FRA:0VQ) told investors that its founded entity Seaport Therapeutics has priced an upsized US initial public offering at the top of its target range, putting the clinical-stage neuropsychiatry company on course to raise gross proceeds of $254.9 million. In London, PureTech shareholders saw the share price climb 9.56% to 139.8p.
Drug developer Seaport Therapeutics said on Thursday it had raised about $255 million in its upsized initial public offering in the United States.
BOSTON--(BUSINESS WIRE)--Seaport Therapeutics Announces Pricing of Upsized Initial Public Offering.
Drug developer Seaport Therapeutics said on Monday it was aiming for a valuation of $912 million in its initial public offering in the United States.
